Communiqués IntelGenx Technologies Corp.

Actions

IGXT

US45822R1014

Marché Fermé - OTC Markets Autres places de cotation 21:57:54 16/05/2024			Varia. 5j.	Varia. 1 janv.
0,167 ^USD	-3,75 %		-.--%	+20,93 %

17/05	IntelGenx Technologies Corp. annonce la démission de membres de son conseil d'administration	CI
17/05	IntelGenx Technologies entame des procédures de restructuration en vertu de la LACC afin de mettre en œuvre un examen de ses options stratégiques	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease	03/07	GL
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process	11/06	GL
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process	28/05	GL
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	17/05	GL
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	17/05	GL
Canadian Investment Regulatory Organization Trading Halt - IGX	17/05	AQ
IntelGenx: Q1 Earnings Snapshot	15/05	AQ
IntelGenx Announces Voting Results on Election of Directors	08/05	GL
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08/04	GL
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08/04	AQ
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04	GL
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21/03	GL
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03	PU
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03	PU
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	14/03	GL
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03	GL
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03	AQ
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20/02	GL
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	05/02	GL
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	05/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués IntelGenx Technologies Corp.

Actions

IGXT

US45822R1014

Communiqués

Filtres